CoChat
Sign Up
Cited by 65Pancreatic function and diabetesDiabetes Management and ResearchDiabetes and associated disorders

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Impact of Islet Transplantation on Diabetes Complications and Quality of Life

Bassi, Roberto, Fiorina, Paolo·2011·Current Diabetes Reports
DOI 10.1007/s11892-011-0211-1
Open this paper in CoChat — free account

Abstract

Insulin represents a life-saving therapy for patients with type 1 diabetes but, despite appropriate treatment, it prevents only partially long-term diabetic complications, while generating fatal hypoglycemic episodes. Islet transplantation gained attention because of its safety, effectiveness, and minimal invasiveness; however it remains a procedure reserved for a selected group of patients. The introduction of the Edmonton Protocol in 2000, based on a newly designed steroid-free immunosuppressive protocol, revamped the course of islet transplantation. The main goal of islet transplantation remains insulin independence, although the effect of islet transplantation can be more comprehensively evaluated in terms of frequency of hypoglycemic episodes and impact on diabetic complications and quality of life. Islet transplantation was shown to have positive consequences on cardiovascular, renal, neurologic, and ocular diabetic complications. The proof of concept for cellular replacement therapy in diabetes has been established with islet transplantation, it only needs to be improved and rendered widely available.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11892-011-0211-1

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 75

  1. Bloomgarden ZT. Diabetes complications. Diabetes Care. 2004;27:1506–14. · DOI
  2. Kemp CB, Knight MJ, Scharp DW, Ballinger WF, Lacy PE. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia. 1973;9:486–91. · DOI
  3. Najarian JS, Sutherland DE, Matas AJ, Steffes MW, Simmons RL, Goetz FC. Human islet transplantation: a preliminary report. Transplant Proc. 1977;9:233–6.
  4. Largiader F, Kolb E, Binswanger U, Illig R. Successful allotransplantation of an island of Langerhans. Schweiz Med Wochenschr. 1979;109:1733–6.
  5. Scharp DW, Lacy PE, Santiago JV, et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes. 1990;39:515–8. · DOI
  6. Pyzdrowski KL, Kendall DM, Halter JB, Nakhleh RE, Sutherland DE, Robertson RP. Preserved insulin secretion and insulin independence in recipients of islet autografts. N Engl J Med. 1992;327:220–6. · DOI
  7. Tzakis AG, Ricordi C, Alejandro R, et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet. 1990;336:402–5. · DOI
  8. Ricordi C, Tzakis AG, Carroll PB, et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation. 1992;53:407–14. · DOI
  9. Oberholzer J, Triponez F, Mage R, et al. Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations. Transplantation. 2000;69:1115–23. · DOI
  10. Oberholzer J, Toso C, Triponez F, et al. Human islet allotransplantation with Basiliximab in type I diabetic patients with end-stage renal failure. Transplant Proc. 2002;34:823–5. · DOI
  11. Benhamou PY, Oberholzer J, Toso C, et al. Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999–2000). Groupe de Recherche Rhin Rhjne Alpes Geneve pour la transplantation d’Ilots de Langerhans. Diabetologia. 2001;44:859–64. · DOI
  12. Hering BJ, Bretzel RG, Hopt UT, et al. New protocol toward prevention of early human islet allograft failure. Transplant Proc. 1994;26:570–1.
  13. Bretzel RG, Brandhorst D, Brandhorst H, et al. Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management. J Mol Med. 1999;77:140–3. · DOI
  14. Secchi A, Socci C, Maffi P, et al. Islet transplantation in IDDM patients. Diabetologia. 1997;40:225–31. · DOI
  15. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230–8. · DOI · Paper page
  16. Lee TC, Barshes NR, Brunicardi FC, et al. Procurement of the human pancreas for pancreatic islet transplantation. Transplantation. 2004;78:481–3. · DOI
  17. Venturini M, Angeli E, Maffi P, et al. Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US. Radiology. 2005;234:617–24. · DOI
  18. Robertson RP. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes. 2010;59:1285–91. · DOI
  19. Hafiz MM, Faradji RN, Froud T, et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation. 2005;80:1718–28. · DOI
  20. Lakey JR, Mirbolooki M, Shapiro AM. Current status of clinical islet cell transplantation. Methods Mol Biol. 2006;333:47–104.
  21. Berney T, Toso C. Monitoring of the islet graft. Diabetes Metab. 2006;32:503–12. · DOI
  22. Vantyghem MC, Kerr-Conte J, Arnalsteen L, et al. Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care. 2009;32:1473–8. · DOI
  23. Naftanel MA, Harlan DM. Pancreatic islet transplantation. PLoS Med. 2004;1:e58; quiz e75. · DOI
  24. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86. · DOI · Paper page
  25. • Fiorina P, Shapiro AM, Ricordi C, Secchi A. The clinical impact of islet transplantation. Am J Transplant. 2008;8:1990–7. This work comprehensively reviews the state of the art of islet transplantation, immunosuppression, outcomes, and their impact on patients’ survival and long-term diabetic complications. · DOI
  26. Hering BJ, Browatzki CC, Schultz A, Bretzel RG, Federlin KF. Clinical islet transplantation–registry report, accomplishments in the past and future research needs. Cell Transplant. 1993;2:269–82. discussion 83–305. · DOI
  27. Gaston RS, Basadonna G, Cosio FG, et al. Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. Am J Kidney Dis. 2004;44:529–42. · DOI
  28. Robertson RP. Update on transplanting beta cells for reversing type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39:655–67. · DOI
  29. Maffi P, Bertuzzi F, De Taddeo F, et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care. 2007;30:1150–5. · DOI
  30. Robertson RP. Islet transplantation as a treatment for diabetes—a work in progress. N Engl J Med. 2004;350:694–705. · DOI
  31. Brunicardi FC, Atiya A, Stock P, et al. Clinical islet transplantation experience of the University of California Islet Transplant Consortium. Surgery. 1995;118:967–71. discussion 71–2. · DOI
  32. Goss JA, Goodpastor SE, Brunicardi FC, et al. Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center. Transplantation. 2004;77:462–6. · DOI
  33. Shapiro AM, Ricordi C, Hering B. Edmonton’s islet success has indeed been replicated elsewhere. Lancet. 2003;362:1242. · DOI
  34. Toso C, Baertschiger R, Morel P, et al. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Am J Transplant: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2006;6:1049–58. · DOI
  35. Gerber PA, Pavlicek V, Demartines N, et al. Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia. 2008;51:110–9. · DOI
  36. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2005;5:2037–46. · DOI
  37. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2004;4:390–401. · DOI
  38. Bellin MD, Kandaswamy R, Parkey J, et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant. 2008;8:2463–70. · DOI
  39. Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant. 2008;8:1250–61. · DOI
  40. Skyler JS, Greenbaum CJ, Lachin JM, et al. Type 1 Diabetes TrialNet–an international collaborative clinical trials network. Ann N Y Acad Sci. 2008;1150:14–24. · DOI
  41. Oberholzer J, Kinzer K, Fiorina P. The anti-LFA-1 trial in islet transplantation. Am J Transplant. 2010;10:1725–6. · DOI
  42. •• Alejandro R, Barton FB, Hering BJ, Wease S. 2008 Update from the Collaborative Islet Transplant Registry. Transplantation 2008;86:1783–8. This paper summarizes the most recent update from the CITR and represents the most complete collection of information on islet transplantation. · DOI
  43. Davalli AM, Maffi P, Socci C, et al. Insights from a successful case of intrahepatic islet transplantation into a type 1 diabetic patient. J Clin Endocrinol Metab. 2000;85:3847–52. · DOI
  44. Berney T, Ferrari-Lacraz S, Buhler L, et al. Long-term insulin-independence after allogeneic islet transplantation for type 1 diabetes: over the 10-year mark. Am J Transplant. 2009;9:419–23. · DOI
  45. Alejandro R, Lehmann R, Ricordi C, et al. Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes. 1997;46:1983–9. · DOI
  46. Luzi L, Perseghin G, Brendel MD, et al. Metabolic effects of restoring partial beta-cell function after islet allotransplantation in type 1 diabetic patients. Diabetes. 2001;50:277–82. · DOI
  47. Rickels MR, Schutta MH, Markmann JF, Barker CF, Naji A, Teff KL. {beta}-Cell function following human islet transplantation for type 1 diabetes. Diabetes. 2005;54:100–6. · DOI
  48. Poggioli R, Faradji RN, Ponte G, et al. Quality of life after islet transplantation. Am J Transplant: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2006;6:371–8. · DOI
  49. Geiger MC, Ferreira JV, Hafiz MM, et al. Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation. Cell Transplant. 2005;14:77–84. · DOI
  50. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53:955–62. · DOI
  51. Poggioli R, Faradji RN, Ponte G, et al. Quality of life after islet transplantation. Am J Transplant. 2006;6:371–8. · DOI
  52. Barshes NR, Vanatta JM, Mote A, et al. Health-related quality of life after pancreatic islet transplantation: a longitudinal study. Transplantation. 2005;79:1727–30. · DOI
  53. Johnson JA, Kotovych M, Ryan EA, Shapiro AM. Reduced fear of hypoglycemia in successful islet transplantation. Diabetes Care. 2004;27:624–5. · DOI
  54. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321–6.
  55. Teran-Escandon D, Teran-Ortiz L, Ormsby-Jenkins C, Evia-Viscarra ML, White DJ, Valdes-Gonzalez-Salas R. Psychosocial aspects of xenotransplantation: survey in adolescent recipients of porcine islet cells. Transplant Proc. 2005;37:521–4. · DOI
  56. Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group. Diabetes Care 1988;11:725–32.
  57. Toso C, Shapiro AM, Bowker S, et al. Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome. Transplantation. 2007;84:664–6. · DOI
  58. Cure P, Pileggi A, Froud T, et al. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation. Transplantation. 2008;85:801–12. · DOI
  59. Tharavanij T, Betancourt A, Messinger S, et al. Improved long-term health-related quality of life after islet transplantation. Transplantation. 2008;86:1161–7. · DOI
  60. Melton 3rd LJ, Macken KM, Palumbo PJ, Elveback LR. Incidence and prevalence of clinical peripheral vascular disease in a population-based cohort of diabetic patients. Diabetes Care. 1980;3:650–4. · DOI
  61. Fiorina P, Gremizzi C, Maffi P, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care. 2005;28:1358–65. · DOI
  62. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328:1676–85. · DOI
  63. Fiorina P, Folli F, D’Angelo A, et al. Normalization of multiple hemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation. Diabetes. 2004;53:2291–300. · DOI
  64. Fiorina P, Folli F, Zerbini G, et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol. 2003;14:2150–8. · DOI
  65. Fiorina P, Venturini M, Folli F, et al. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care. 2005;28:1303–10. · DOI
  66. Fung MA, Warnock GL, Ao Z, et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: an interim report. Transplantation. 2007;84:17–22. · DOI
  67. Leitao CB, Cure P, Messinger S, et al. Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management. Transplantation. 2009;87:681–8. · DOI
  68. Senior PA, Zeman M, Paty BW, Ryan EA, Shapiro AM. Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant. 2007;7:91–8. · DOI
  69. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia. 2000;43:957–73. · DOI · Paper page
  70. Lee TC, Barshes NR, O’Mahony CA, et al. The effect of pancreatic islet transplantation on progression of diabetic retinopathy and neuropathy. Transplant Proc. 2005;37:2263–5. · DOI
  71. Del Carro U, Fiorina P, Amadio S, et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care. 2007;30:3063–9. · DOI
  72. McCall AL. Diabetes mellitus and the central nervous system. Int Rev Neurobiol. 2002;51:415–53. · DOI
  73. Franceschi M, Cecchetto R, Minicucci F, Smizne S, Baio G, Canal N. Cognitive processes in insulin-dependent diabetes. Diabetes Care. 1984;7:228–31. · DOI
  74. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–36. · DOI · Paper page
  75. Venturini M, Fiorina P, Maffi P, et al. Early increase of retinal arterial and venous blood flow velocities at color Doppler imaging in brittle type 1 diabetes after islet transplant alone. Transplantation. 2006;81:1274–7. · DOI

Cited by

Sorted by citations

Metadata

Authors
Bassi, R., & Fiorina, P.
Affiliations
Boston Children's Hospital (US)
Corresponding author
Fiorina, Paolo
ORCID
Venue
Current Diabetes Reports
Publisher
Springer Science and Business Media LLC
Published
2011-07-12
Volume
11
Issue
5
Pages
355-363
ISSN
  • 1534-4827 (ISSN-L)
  • 1539-0829
DOI
10.1007/s11892-011-0211-1
OpenAlex
W1969769948
Cited by
65
References
3
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2022: 3 · 2021: 5 · 2020: 2 · 2019: 9 · 2018: 9 · 2017: 9 · 2016: 6 · 2015: 4 · 2014: 4 · 2013: 8 · 2012: 2
FWCI
4.91
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Diabetes Reports (publishedVersion)
  • PubMed (publishedVersion)
Funders
Ministero dell’Istruzione, dell’Università e della Ricerca
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
islet transplantation, type 1 diabetes, diabetes complications, quality of life, hypoglycemia, Edmonton protocol, steroid-free immunosuppression, insulin independence, cardiovascular complications, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy
MeSH terms
Diabetes Mellitus, Type 1, Humans, Immunosuppressive Agents, Quality of Life, Islets of Langerhans Transplantation, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review